News of Novartis AG' $2.1bn acquisition of Endocyte Inc., and the company's corresponding expansion into radiopharmaceuticals, dominated much of the discussion during the drug maker's third quarter earnings call Oct. 18. But the company's plate is chock full, with several high-profile drug launches underway.
The company provided updates on a number of commercial-stage drugs, including Cosentyx (secukinumab), Kymriah (tisagenlecleucel), Kisqali (ribociclib) and Aimovig (erenumab), as well as announcing regulatory news on its late-stage pipeline candidates, the gene therapy AVXS-101 and canakinumab
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
